Intismeran phase 3 win accelerates personalized cancer vaccine momentum
TL;DR Summary
Merck and Moderna announced that the intismeran (mRNA-4157) adjuvant vaccine, when combined with Keytruda, improved recurrence-free survival and distant metastasis-free survival in a phase 3 melanoma trial, renewing optimism for personalized neoantigen vaccines and potentially reshaping oncology if data readouts support broader use; regulators will be engaged for potential approvals, and the news spurred biotech stock gains while highlighting a growing field of mRNA cancer therapies from Arcturus, BioNTech, Strand Therapeutics and others.
- Is Moderna, Merck's mRNA cancer vaccine win the start of a 'personalized medicine revolution'? Fierce Biotech
- Clinical trials: New mRNA cancer vaccine plus Keytruda sharply improves melanoma survival UCHealth
- mRNA cancer vaccines’ biggest barriers to market BioPharma Dive
- A vaccine trial for melanoma shows it can slow down cancer growth: HealthLink KING5.com
- The data from Moderna and Merck’s trial have yet to be presented The Cancer Letter
Reading Insights
Total Reads
1
Unique Readers
11
Time Saved
10 min
vs 10 min read
Condensed
96%
2,000 → 73 words
Want the full story? Read the original article
Read on Fierce Biotech